The Medicines Company (MDCO) 02-02-17

 Comments Off on The Medicines Company (MDCO) 02-02-17
Feb 022017
 
The Medicines Company (MDCO) 02-02-17

BIOINVEST Update – The Medicines Company (MDCO) – Amgen’s FOURIER Outcomes Trial Successful – After the close, AMGN announced the long-awaited results of the outcomes trial with Repatha – its PCSK9 monoclonal antibody.

The Medicines Company (MDCO) 11-07-16

 Comments Off on The Medicines Company (MDCO) 11-07-16
Nov 082016
 
The Medicines Company (MDCO) 11-07-16

BIOINVEST Update – The Medicines Company (MDCO) – – Discontinues ‘216 – AHA Meeting Next Week

News – MDCO Stops MDCO-216 After Pilot Trial Unsuccessful – The pilot trial did not show efficacy – there was no positive effect on atherosclerosis. Safety was fine. The data calls into question the viability of APO-A1 Milano as a target and the positive implications of HDL as well.

Madrigal Pharmaceuticals (MDGL) 10-25-16

 Comments Off on Madrigal Pharmaceuticals (MDGL) 10-25-16
Oct 252016
 
Madrigal Pharmaceuticals (MDGL) 10-25-16

BIOINVEST Update – (New Recommendation) Madrigal Pharmaceuticals (MDGL) – Paul Friedman Is Back

NASH is a hot topic in Biotech since September when Allergan bought Tobira Therapeutics (TBRA) for a stunning $1.7 billion for a Phase II asset. The Tobira deal was done at a tremendous 500% premium and topped the $1.2 billion Gilead paid for a NASH drug candidate being developed by Nimbus Therapeutics.

‘Access to Management’ Conference Call with Anthera (ANTH) 9-1-16

 Comments Off on ‘Access to Management’ Conference Call with Anthera (ANTH) 9-1-16
Sep 012016
 
'Access to Management' Conference Call with Anthera (ANTH) 9-1-16

BIOINVEST Access to Management Webinar – Anthera (ANTH)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Anthera.

Ziopharm (ZIOP) (7-15-16)

 Comments Off on Ziopharm (ZIOP) (7-15-16)
Jul 152016
 
Ziopharm (ZIOP) (7-15-16)

BIOINVEST BREAKING NEWS – Special Update – Ziopharm (ZIOP) – 3 Patients Die In The IL-12 Trial. ZIOP is down sharply this morning (7/15) on the report that three patients have died in their ongoing multicenter Phase I trial of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.

‘Access to Management’ Conference Call with Novavax (NVAX) 6-3-16

 Comments Off on ‘Access to Management’ Conference Call with Novavax (NVAX) 6-3-16
Jun 072016
 
'Access to Management' Conference Call with Novavax (NVAX) 6-3-16

BIOINVEST Access to Management Webinar – Novavax (NVAX)– We are pleased to announce another BioInvest “Access to Management Call.” Below is the link to the recorded webinar presentation with the Senior Management Team of Novavax.

Ziopharm (ZIOP) (5-16-16)

 Comments Off on Ziopharm (ZIOP) (5-16-16)
May 172016
 
Ziopharm (ZIOP) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ZIOP – Shows Rather Impressive Preclinical Data at ASGCT, Up Next Human Data at ASCO.
ZIOP was front and center at the 2016 Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington D.C. last week. The company presented exciting preclinical data for IL-12 in combo with a PD-1 that showed 100% survival. The non-viral Sleeping Beauty (SB) system was also on display. Read more…

Novavax Update (5-16-16)

 Comments Off on Novavax Update (5-16-16)
May 172016
 
Novavax Update (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – NVAX – Q1 Call – Preparing For The Launch Of The RSV Vaccine With Partners In The Wings; We Are In The Zone Read more…

Anthera Update (5-16-16)

 Comments Off on Anthera Update (5-16-16)
May 172016
 
Anthera Update (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ANTH — As IgAN Data Nears, The Case For A Reduction In Proteinuria. With Anthera shortly delivering its first new clinical trial results in a long time, the implications of the IgAN data, in our opinion the implications of the IgAN data, while not yet valued by investors, are many. Read more…

Anacor (ANAC) Buyout By Pfizer (PFE) (5-16-16)

 Comments Off on Anacor (ANAC) Buyout By Pfizer (PFE) (5-16-16)
May 162016
 
Anacor  (ANAC) Buyout By Pfizer (PFE) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Intrexon Update (4-21-16)

 Comments Off on Intrexon Update (4-21-16)
Apr 222016
 
Intrexon Update (4-21-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Ionis Update (3-23-16)

 Comments Off on Ionis Update (3-23-16)
Mar 232016
 
Ionis Update (3-23-16)

IONS Huge Winner as GILD Ruled to Infringe on IONS/Merck HCV Patent –Yesterday, a California District Court jury determined GILD’s blockbuster hepatitis C drugs Sovaldi and Harvoni infringe on two Merck/IONS patents. Read more…

Intrexon Update (1-7-16)

 Comments Off on Intrexon Update (1-7-16)
Jan 202016
 
Intrexon Update (1-7-16)

Intrexon (XON) – Two Health Care Deals Signed For Metabolic Diseases and RA – The first deal is with Janssen Pharmaceutica NV (JNJ’s Euro Division) is to discover and develop ActoBiotics therapies directed against selected targets to treat Type 2 diabetes (T2D), obesity and/or metabolic disorders related to energy dysregulation. XON’s ActoBiotics platform represents an innovative oral delivery system for biological effectors ideally suited to tackle multiple aspects of T2D with the potential to improve efficacy in maintaining glycemic control in the long term. Read more…

Five Prime Update (1-7-16)

 Comments Off on Five Prime Update (1-7-16)
Jan 202016
 
Five Prime Update (1-7-16)

Five Prime (FPRX) – Poised For Big Time 2016; Raising Buy & Target – FPRX had a great year in 2015 with the BMS deal being one of the best we have ever seen for a Phase I compound. The company continues to click on all cylinders and in our view, with the strength and depth of that deal, the Company is gaining further momentum. Early 2016 is ripe with three clinical trials releases that should serve as important catalysts to begin the year. Read more…

Anthera Update (1-07-16)

 Comments Off on Anthera Update (1-07-16)
Jan 202016
 
Anthera Update (1-07-16)

Anthera (ANTH) Strengthens Senior Management With President/COO & Chief Technology Officer – Craig Thompson is joining ANTH as President and Chief Operating Officer. He comes with an experienced Big Pharma strategic marketing background (~10 years at Merck, ~8 at Pfizer), and will oversee both of the Company’s late-stage development programs and commercial preparation efforts. read more…